PL3555097T3 - Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych - Google Patents
Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowychInfo
- Publication number
- PL3555097T3 PL3555097T3 PL17854175.1T PL17854175T PL3555097T3 PL 3555097 T3 PL3555097 T3 PL 3555097T3 PL 17854175 T PL17854175 T PL 17854175T PL 3555097 T3 PL3555097 T3 PL 3555097T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrrolo
- imidazo
- inhibitors
- pyridine compounds
- janus kinases
- Prior art date
Links
- DACYIWKCVUOZIP-UHFFFAOYSA-N 3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,3,5,7,9,11-hexaene Chemical class C1=NC2=NC=CC2=C2N=CN=C21 DACYIWKCVUOZIP-UHFFFAOYSA-N 0.000 title 1
- 102000015617 Janus Kinases Human genes 0.000 title 1
- 108010024121 Janus Kinases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435609P | 2016-12-16 | 2016-12-16 | |
| US201762592680P | 2017-11-30 | 2017-11-30 | |
| US201762596607P | 2017-12-08 | 2017-12-08 | |
| PCT/US2017/066744 WO2018112379A1 (en) | 2016-12-16 | 2017-12-15 | Small molecule inhibitors of the jak family of kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3555097T3 true PL3555097T3 (pl) | 2022-10-17 |
Family
ID=61692222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17854175.1T PL3555097T3 (pl) | 2016-12-16 | 2017-12-15 | Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US10294226B2 (pl) |
| EP (2) | EP4086256A1 (pl) |
| JP (2) | JP7291077B2 (pl) |
| KR (1) | KR102352462B1 (pl) |
| CN (1) | CN110088105B (pl) |
| AU (3) | AU2017377069B2 (pl) |
| CL (1) | CL2019001626A1 (pl) |
| CO (1) | CO2019006200A2 (pl) |
| CR (1) | CR20190282A (pl) |
| CY (1) | CY1125460T1 (pl) |
| DK (1) | DK3555097T3 (pl) |
| EC (1) | ECSP19042688A (pl) |
| ES (1) | ES2922379T3 (pl) |
| HR (1) | HRP20220885T1 (pl) |
| HU (1) | HUE059274T2 (pl) |
| IL (1) | IL267275B (pl) |
| JO (1) | JOP20190143B1 (pl) |
| LT (1) | LT3555097T (pl) |
| MD (1) | MD3555097T2 (pl) |
| MX (2) | MX2022004474A (pl) |
| MY (1) | MY196260A (pl) |
| NI (1) | NI201900060A (pl) |
| NZ (1) | NZ795615A (pl) |
| PE (1) | PE20191105A1 (pl) |
| PH (1) | PH12019501254A1 (pl) |
| PL (1) | PL3555097T3 (pl) |
| PT (1) | PT3555097T (pl) |
| RS (1) | RS63500B1 (pl) |
| SA (1) | SA519402216B1 (pl) |
| SI (1) | SI3555097T1 (pl) |
| SM (1) | SMT202200326T1 (pl) |
| TW (1) | TWI777997B (pl) |
| UA (1) | UA125042C2 (pl) |
| WO (1) | WO2018112379A1 (pl) |
| ZA (1) | ZA201904615B (pl) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ751284A (en) | 2016-10-03 | 2022-09-30 | Hangzhou Highlightll Pharmaceutical Co Ltd | Novel jak1 selective inhibitors and uses thereof |
| JOP20190090B1 (ar) | 2016-10-24 | 2023-03-28 | Astrazeneca Ab | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان |
| JP7291077B2 (ja) | 2016-12-16 | 2023-06-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｊａｋファミリーのキナーゼの低分子阻害物質 |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| EP3689873B1 (en) | 2017-01-30 | 2022-09-14 | Astrazeneca AB | Estrogen receptor modulators |
| CN112654610B (zh) | 2018-06-15 | 2024-12-24 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
| TW202016110A (zh) * | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| WO2020216936A1 (en) | 2019-04-24 | 2020-10-29 | Janssen Pharmaceutica Nv | Non-clinical liquid formulations of pan-jak inhibitor |
| KR102785014B1 (ko) | 2019-06-06 | 2025-03-20 | 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. | 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태 |
| CN110483514B (zh) | 2019-09-16 | 2022-06-14 | 启元生物(杭州)有限公司 | 一种氰基取代的环肼衍生物及其应用 |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| AU2021222686B2 (en) * | 2020-02-21 | 2023-06-29 | Zhuhai United Laboratories Co., Ltd. | Crystalline form of JAK inhibitor and application thereof |
| MX2022013258A (es) | 2020-04-24 | 2022-11-14 | Astrazeneca Ab | Formulaciones farmaceuticas. |
| JP7712955B2 (ja) | 2020-04-24 | 2025-07-24 | アストラゼネカ・アクチエボラーグ | 癌の治療のための投薬レジメン |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CN116925077A (zh) * | 2020-09-08 | 2023-10-24 | 一又生物(上海)有限公司 | 吡啶并环类化合物及其制备方法、中间体、组合物和应用 |
| AU2022233254A1 (en) | 2021-03-11 | 2023-10-26 | Janssen Pharmaceutica Nv | Lorpucitinib for use in the treatment of jak mediated disorders |
| CN113292561A (zh) * | 2021-05-22 | 2021-08-24 | 中国药科大学 | 一种二吡咯并吡啶结构的化合物、制备方法和医药用途 |
| CN114432317A (zh) * | 2021-05-31 | 2022-05-06 | 广州嘉越医药科技有限公司 | 吡咯并嘧啶类化合物的用途 |
| CN113861194B (zh) * | 2021-11-10 | 2022-07-05 | 英维沃化工科技(广州)有限公司 | 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| PL351684A1 (en) | 1999-04-23 | 2003-06-02 | Smithkline Beecham Plc | Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US7192962B2 (en) | 2002-05-31 | 2007-03-20 | Schering Corporation | Xanthine phosphodiesterase V inhibitor polymorphs |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
| WO2007005462A1 (en) | 2005-07-01 | 2007-01-11 | Wyeth | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same |
| KR20080026654A (ko) * | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| RU2015105591A (ru) | 2008-06-10 | 2015-08-10 | Эббви Инк. | Новые трициклические соединения |
| BR112012004970B1 (pt) | 2009-09-03 | 2020-09-01 | Bristol-Myers Squibb Company | Inibidores de jak2, seu uso no tratamento de doenças mieloproliferativas e câncer composição farmacêutica que os compreende |
| JP2011066747A (ja) * | 2009-09-18 | 2011-03-31 | Panasonic Corp | 弾性波フィルタ |
| JP5607174B2 (ja) | 2009-12-01 | 2014-10-15 | アッヴィ・インコーポレイテッド | 新規な三環式化合物 |
| AU2010326030A1 (en) | 2009-12-01 | 2012-06-07 | Abbvie Inc. | Novel tricyclic compounds |
| WO2011086053A1 (en) | 2010-01-12 | 2011-07-21 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| EP2534258B1 (en) | 2010-02-10 | 2017-09-20 | Genon Biotechnologies OY | Dual activity kinase domains and uses thereof |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| EP2955181B1 (en) | 2013-02-08 | 2019-10-30 | Nissan Chemical Corporation | Tricyclic pyrrolopyridine compound, and jak inhibitor |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| WO2015174376A1 (ja) | 2014-05-14 | 2015-11-19 | 日産化学工業株式会社 | ３環性化合物及びｊａｋ阻害剤 |
| KR20180011272A (ko) | 2015-05-28 | 2018-01-31 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 키나제 저해제로서 나프티리딘 화합물 |
| WO2017079639A1 (en) | 2015-11-04 | 2017-05-11 | Mayo Foundation For Medical Education And Research | Methods and materials for treating autoimmune conditions |
| JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| JOP20190090B1 (ar) | 2016-10-24 | 2023-03-28 | Astrazeneca Ab | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان |
| JP7291077B2 (ja) | 2016-12-16 | 2023-06-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｊａｋファミリーのキナーゼの低分子阻害物質 |
| US20200077658A1 (en) | 2016-12-16 | 2020-03-12 | Basf Se | Pesticidal Compounds |
| PH12019501328B1 (en) | 2016-12-16 | 2023-05-12 | Lilly Co Eli | 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors |
| BR112019010627B1 (pt) | 2016-12-16 | 2023-05-02 | Société des Produits Nestlé S.A. | Uso de um iso-oligossacarídeo, e método para geração de sabor em um produto alimentício termicamente tratado |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| CN110325530B (zh) | 2016-12-16 | 2022-01-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
| CA3045567A1 (en) | 2017-01-11 | 2018-07-19 | Leo Pharma A/S | Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof |
| EP3689873B1 (en) | 2017-01-30 | 2022-09-14 | Astrazeneca AB | Estrogen receptor modulators |
| FI3612030T3 (fi) | 2017-04-21 | 2026-03-20 | Pahr Therapeutics Inc | Ahr:n indoliestäjiä ja niiden käyttötapoja |
| CN106881892B (zh) | 2017-04-27 | 2020-10-16 | 双钱集团（江苏）轮胎有限公司 | 一种轮胎生产用生胎转移系统 |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| WO2020216936A1 (en) | 2019-04-24 | 2020-10-29 | Janssen Pharmaceutica Nv | Non-clinical liquid formulations of pan-jak inhibitor |
-
2017
- 2017-12-15 JP JP2019531668A patent/JP7291077B2/ja active Active
- 2017-12-15 PL PL17854175.1T patent/PL3555097T3/pl unknown
- 2017-12-15 US US15/843,642 patent/US10294226B2/en active Active
- 2017-12-15 DK DK17854175.1T patent/DK3555097T3/da active
- 2017-12-15 TW TW106144095A patent/TWI777997B/zh active
- 2017-12-15 EP EP22178880.5A patent/EP4086256A1/en active Pending
- 2017-12-15 CR CR20190282A patent/CR20190282A/es unknown
- 2017-12-15 PE PE2019001252A patent/PE20191105A1/es unknown
- 2017-12-15 UA UAA201908086A patent/UA125042C2/uk unknown
- 2017-12-15 EP EP17854175.1A patent/EP3555097B1/en active Active
- 2017-12-15 SM SM20220326T patent/SMT202200326T1/it unknown
- 2017-12-15 MY MYPI2019003389A patent/MY196260A/en unknown
- 2017-12-15 SI SI201731186T patent/SI3555097T1/sl unknown
- 2017-12-15 AU AU2017377069A patent/AU2017377069B2/en active Active
- 2017-12-15 KR KR1020197020121A patent/KR102352462B1/ko active Active
- 2017-12-15 HU HUE17854175A patent/HUE059274T2/hu unknown
- 2017-12-15 PT PT178541751T patent/PT3555097T/pt unknown
- 2017-12-15 MX MX2022004474A patent/MX2022004474A/es unknown
- 2017-12-15 ES ES17854175T patent/ES2922379T3/es active Active
- 2017-12-15 RS RS20220753A patent/RS63500B1/sr unknown
- 2017-12-15 CN CN201780077753.4A patent/CN110088105B/zh active Active
- 2017-12-15 HR HRP20220885TT patent/HRP20220885T1/hr unknown
- 2017-12-15 NZ NZ795615A patent/NZ795615A/en unknown
- 2017-12-15 MX MX2019007073A patent/MX391936B/es unknown
- 2017-12-15 LT LTEPPCT/US2017/066744T patent/LT3555097T/lt unknown
- 2017-12-15 JO JOP/2019/0143A patent/JOP20190143B1/ar active
- 2017-12-15 WO PCT/US2017/066744 patent/WO2018112379A1/en not_active Ceased
- 2017-12-15 MD MDE20191212T patent/MD3555097T2/ro unknown
-
2019
- 2019-01-09 US US16/243,874 patent/US10364246B2/en active Active
- 2019-02-12 US US16/274,142 patent/US11059823B2/en active Active
- 2019-02-13 US US16/275,045 patent/US10487083B2/en active Active
- 2019-06-06 PH PH12019501254A patent/PH12019501254A1/en unknown
- 2019-06-12 CL CL2019001626A patent/CL2019001626A1/es unknown
- 2019-06-12 IL IL267275A patent/IL267275B/en unknown
- 2019-06-13 SA SA519402216A patent/SA519402216B1/ar unknown
- 2019-06-14 EC ECSENADI201942688A patent/ECSP19042688A/es unknown
- 2019-06-14 NI NI201900060A patent/NI201900060A/es unknown
- 2019-06-14 CO CONC2019/0006200A patent/CO2019006200A2/es unknown
- 2019-07-15 ZA ZA2019/04615A patent/ZA201904615B/en unknown
-
2020
- 2020-10-21 AU AU2020257068A patent/AU2020257068A1/en not_active Abandoned
-
2021
- 2021-06-23 US US17/355,472 patent/US12202831B2/en active Active
-
2022
- 2022-06-17 AU AU2022204240A patent/AU2022204240B2/en active Active
- 2022-08-02 CY CY20221100530T patent/CY1125460T1/el unknown
-
2023
- 2023-02-13 JP JP2023019626A patent/JP7493068B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202200326T1 (it) | Composti imidazo[4,5-d]pirrolo[2,3-b]piridinici come inibitori di chinasi janus | |
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| IL265918A (en) | Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors | |
| SG11202101148UA (en) | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | |
| ZA201800771B (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| IL255305B (en) | Synthesis of kinase-modulating h1-pyrrolo[3,2-b]pyridine derivatives | |
| DK3478682T3 (da) | [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| LT2958921T (lt) | Pirolo[2, 3 -d]pirimidino dariniai, kaip janus kinazės (jak) inhibitoriai | |
| PL3371185T3 (pl) | Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych | |
| PL3712152T3 (pl) | Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych | |
| SG11201606216UA (en) | Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors | |
| IL247948B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors | |
| IL290419A (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta | |
| EP3856743A4 (en) | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | |
| IL272988A (en) | Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors |